These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
It provides Covid-19 detection and Omicron surveillance in less than two hours
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
